NEW YORK, NY -- (Marketwire) -- 07/20/12 -- The Biotech Industry has been soaring this year as companies -- both large and small -- have shown impressive gains. Companies focusing on the anti-obesity drug market have been gaining popularity among investors recently as there have been two drugs approved by the FDA in the past month. Five Star Equities examines the outlook for companies in the Biotech Industry and provides equity research on Orexigen Therapeutics, Inc. (NASDAQ: OREX) and Roche Holding Ltd. (PINKSHEETS: RHHBY).
Access to the full company reports can be found at:
According to data from the World Health Organization globally there are approximately 1.4 billion people classified as overweight, and 500 million that are obese. "By 2030, 50 to 60 percent of the populations in many countries are on target to be classified as obese," says a recent report from Bank of America Merrill Lynch.
"Obesity may be the most pressing health challenge facing the world today and efforts to tackle it will shape thinking by policymakers and in boardrooms around the world," said Sarbjit Nahal, equity strategist at BofA Merrill Lynch Global Research. "Global obesity is a mega-investment theme for the next 25 years and beyond."
Five Star Equities releases regular market updates on the Biotech Industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.FiveStarEquities.com and get exclusive access to our numerous stock reports and industry newsletters.
Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead product candidate is Contrave, which has completed Phase III clinical trials and for which a New Drug Application has been submitted and reviewed by the FDA. Shares of the company are up over 330 percent this year.
Roche is the world's largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche Holding AG's Xenical was the first anti-obesity drug approved by the FDA in 1999. The FDA recently approved Perjeta for the treatment of people with HER2-positive metastatic breast cancer.
Five Star Equities provides Market Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. Five Star Equities has not been compensated by any of the above-mentioned companies. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at:
Add to Digg Bookmark with del.icio.us Add to Newsvine
Five Star Equities